Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 25,190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: Neurofibromatosis Type II
Interventions: Everolimus (RAD001) , Afinitor®; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 3 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Fasting, Breast Cancer, Survivorship, Breast Cancer Recurrent
Interventions: Fasting; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Small Cell Lung Cancer
Interventions: Fenretinide; Drug
Lead sponsor: SciTech Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Los Angeles, California • Detroit, Michigan

Conditions: Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute, Myeloid Leukemia in Relapse (Disorder), Myelodysplastic Syndromes
Interventions: Radiation, Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Treg-enriched donor cell, Unmodified donor T Cell, CD34+ Haplo Peripheral Blood Stem Cell, Melphalan; Radiation · Drug · Biological + 1 more
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Previously-Irradiated, Squamous Cell Carcinoma of the Head and Neck Cancer
Interventions: SBRT, Cetuximab, Docetaxel; Radiation · Drug
Lead sponsor: Heath Skinner; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Cancer, Kidney Cancer
Interventions: Visual, No intervention; Behavioral · Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Wilmington, North Carolina

Conditions: Old Age; Debility, Peripheral Neuropathy
Interventions: Protective Arm Balance Response Training; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 45 Years to 88 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anterior Cruciate Ligament Rupture, Anterior Cruciate Ligament Tear, Anterior Cruciate Ligament Injuries
Interventions: Self-guided pre-habilitation exercise program, Traditional pre-habilitation; Other
Lead sponsor: WellSpan Health; Other
Eligibility: 13 Years to 50 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: York, Pennsylvania

Conditions: Constipation, Bloating
Interventions: Dietary supplement for digestive health, placebo capsule; Dietary Supplement
Lead sponsor: University of Memphis; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Pre-Diabetic
Interventions: Calcitriol capsules, Oral Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 20 Years to 45 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypotension
Interventions: Colloid administration, Crystalloid administration, phenylephrine infusion; Other · Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Point of Care STI Testing
Interventions: Gonorrhea/chlamydia Point-of-Care Testing; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 16 Years to 24 Years
Enrollment: 6,460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: abiraterone acetate, Prednisone; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 205
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 148 more

Conditions: Primary Ovarian Insufficiency, Premature Menopause, Metabolic Complications, Endothelial Function (FMD), Estrogen Replacement Therapy
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 30 Years to 40 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Subject, Human Papillomavirus Infection
Interventions: carrageenan-containing gel, Placebo, Laboratory Biomarker Analysis, Questionnaire Administration; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 19 Years to 35 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Soft Tissue Sarcomas
Interventions: Pazopanib, Trabectedin, Ipilimumab, Nivolumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 1 Year to 30 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Smoking
Interventions: Smoking-Related Messages; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 25 Years
Enrollment: 2,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Extubation
Interventions: Total intravenous anesthesia (TIVA), Sevoflurane initiated intravenous anesthesia (SIIVA); Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Up to 9 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Smoking, Alcohol Drinking, Prescription Drug Abuse, Substance-Related Disorders, Oral Intake Reduced
Interventions: Person-centered inhibitory control training, Active behavioral response training; Behavioral
Lead sponsor: University of Oregon; Other
Eligibility: 35 Years to 55 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Alcohol Drinking, Alcohol Use Disorder
Interventions: Video; Behavioral
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Diego, California

Conditions: Bronchopulmonary Dysplasia
Interventions: Montelukast; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 7 Days and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Asthma
Interventions: Rhinovirus; Biological
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 40 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions: HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30, MDADI-HN, COST-FACIT, Intensity-Modulated Radiation Therapy (Arm A), Chemoradiation (Arm B); Diagnostic Test · Behavioral · Radiation + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2

Prolonged Nightly Fasting in Breast Cancer Survivors

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

IS-free Treg HaploHCT

SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN

Designing Visual Tools to Enhance Cancer Surgeon Decision-making

Protective Arm Balance Responses

Quantifying the Benefits of Supervised vs. Unsupervised Pre-habilitation for Patients With Acute ACL Tears

Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women

Effect of 1,25-dihydroxyvitamin D3, Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons

Spinal Anesthesia Induced Hypotension During Cesarean Section

Point of Care STI Testing

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

Effects of Estrogen on Heart Health in Women With Primary Ovarian Insufficiency

Carrageenan-Containing Gel in Reducing the Rate of HPV Infection in Healthy Participants

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

Young Adults' Responses to Anti-smoking Messages

Total Intravenous Anesthesia (TIVA)/Sevoflurane Initiated Intravenous Anesthesia (SIIVA) in Pediatric Patients

Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life

Alcohol Misuse Intervention in Active Duty US Navy Personnel

Montelukast in Very Low Birthweight Infants

Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma